BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 5, 2008, Pages 526-534

  Reinis M ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BIOVAXID; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; UNCLASSIFIED DRUG;

ARTHRALGIA; B CELL LYMPHOMA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; FEVER; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MYALGIA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SKIN MANIFESTATION;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MICE; VACCINATION;

EID: 53249115363     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. 454353 Favrille completes $16.9 million financing. Favrille Inc PRESS RELEASE 2002 June 11
2. 454489 Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A et al BLOOD 2002 99 5 1517-1526
3. 454493 Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Kwak LW, Young HA, Pennington RW, Weeks SD PROC NATL ACAD SCI USA 1996 93 20 10972-10977
4. 454495 Efficacy of idiotypic vaccination in mice bearing B-cell lymphoma. Khan NA IN VIVO 1989 3 2 117-119
5. 505368 Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R CANCER RES 2002 62 20 5845-5852
6. 533326 Antibody therapy for non-Hodgkin's lymphoma. Ansell SM CURR OPIN MOL THER 2004 6 2 175-181
7. 581577 A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccine with abbreviated course of granulocyte-macrophage colony-stimulating factor adjuvant in follicular non-Hodgkin's lymphoma. Vose J, Bierman P, Hollingsworth M, Ingolia D, Denney D, Kunkel L BLOOD 2002 100 11 Abs 1397
8. 590114 Vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of phase II results and high rate of chemotherapy-induced complete remissions in a controlled, randomized phase III trial. Neelpau SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Sotomayor E, Inghirami G, Muggia F, Watson T, Snow S et al BLOOD 2003 102 11 Abs 4953
9. 640886 BiovaxID vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial. Santos C, Stern L, Katz L, Watson T, Barry G BLOOD 2005 106 11 Abs 2441
10. 646737 Accentia's BiovaxID increases mantle cell lymphoma patient survival. BioVest International Inc PRESS RELEASE 2006 January 24
11. 646877 Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES et al NAT MED 2006 11 9 986-991
12. 667065 FDA grants BioVest's personalized NHL therapy Fast Track status. Accentia BioPharmaceuticals Inc PRESS RELEASE 2006 May 11
13. 678875 Biovest expands BiovaxID NHL trial to Russia. Biovest International Inc PRESS RELEASE 2006 July 18
14. 684296 Accentia Biopharmaceuticals reports Fiscal Third Quarter 2006 Financial Results; Accentia reaches significant milestones, including commercial launch of MD Turbo in late June. Accentia BioPharmaceuticals Inc PRESS RELEASE 2006 August 15
15. 750670 Phase III trial of active immunotherapy (FavId, Id/KLH) following rituximab induction therapy: Clinical responses in patients (pts) with follicular non-Hodgkin's lymphoma (fNHL). Freedman AS, Hamlin PA, Neelapu S, Nichols C, Robertson M, Bergier G, Winter JN, Polikoff J, Lin T, Pohlman B, Esquibel V et al BLOOD 2006 108 11 Abs 2756
16. 770303 Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES et al NAT MED 1999 5 10 1171-1177
17. 770304 Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R N ENGL J MED 1992 327 17 1209-1215
18. 770305 Myeloma proteins as tumor-specific transplantation antigens. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN PROC NATL ACAD SCI USA 1972 69 6 1540-1544
19. 770307 Idiotypic vaccination as a treatment for a B cell lymphoma. George AJ, Folkard SG, Hamblin TJ, Stevenson FK J IMMUNOL 1988 141 6 2168-2174
20. 770316 Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R J CLIN ONCOL 2004 22 23 4717-4724
21. 775448 Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: A therapeutic target. Stevenson GT, Elliott EV, Stevenson FK FED PROC 1977 36 9 2268-2271
22. 775452 Use of rituximab, the new FDA-approved antibody. Leget GA, Czuczman MS CURR OPIN ONCOL 1998 10 6 548-551
23. 775453 Follicular lymphoma: Time for a re-think? Gandhi MK, Marcus RE BLOOD REV 2005 19 3 165-178
24. 775456 Idiotypic vaccination in B-cell malignancies. Bianchi A, Massaia M MOL MED TODAY 1997 3 10 435-441
25. 775458 Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J HEMATOLOGY (AM SOC HEMATOL EDUCATION PROGRAM) 2002 241-262
26. 802223 Biovest to seek conditional approval of BiovaxID for follicular NHL. Biovest International Inc PRESS RELEASE 2007 June 05
27. 804209 Accentia Biopharmaceuticals' majority-owned subsidiary, Biovest, receives request from the Independent Data Monitoring Committee to conduct interim analysis of anti-cancer vaccine, BiovaxID. Biovest International Inc PRESS RELEASE 2007 June 13
28. 804211 Interim analysis planned for phase III BiovaxID trial for NHL. Biovest International Inc PRESS RELEASE 2007 June 13
29. 809823 Biovest's BiovaxID effective in phase III NHL trial. Biovest International Inc PRESS RELEASE 2007 June 28
30. 839618 Biovest halts phase III NHL trial to accelerate BiovaxID approval. Biovest International Inc PRESS RELEASE 2007 October 16
31. 859743 BiovaxID vaccine therapy of follicular lymphoma in first remission: Phase III blinded safety update. Stergiou AM, Neelapu SS, Casciano R, Jaffee MA, Klak LW AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 Abs 4500
32. 862903 Mixed results for Genitope's MyVax in phase III follicular non-Hodgkin's lymphoma trial. Genitope Corp PRESS RELEASE 2007 December 21
33. 865560 Accentia's CEO provides outlook for 2008 including update on sinunase phase 3 blinded trial results on 80% of patients. Accentia BioPharmaceuticals Inc PRESS RELEASE 2008 January 07
34. 875425 Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: Protocol summary and interim report. Neelapu SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Loughran T Jr, Takeshita K, Inghirami G, McGaughey D, Watson TM et al CLIN LYMPHOMA 2005 6 1 61-64
35. 875426 Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES et al NAT MED 1999 5 10 1124-1125
36. 875427 Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R BLOOD 1997 89 9 3129-3135
37. 875430 BiovaxID vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial. Gause BL, Cohen CM, Katz LM, Watson TM, Arikian S, Stergiou AM EXP HEMATOL 2006 34 9 Suppl 1 54
38. 884757 Genitope suspends MyVax development for non-Hodgkin lymphoma. Genitope Corp PRESS RELEASE 2008 March 11
39. 910233 Favrille discontinues development of Specifid for lymphoma. Favrille Inc PRESS RELEASE 2008 May 27
40. 912083 Vaccine therapy for B-cell lymphomas: Next-generation strategies. Neelapu SS, Kwak LW HEMATOLOGY (AM SOC HEMATOL EDUCATION PROGRAM) 2007 243-249
41. 912096 Therapeutic vaccine for lymphoma. Lee ST, Neelapu SS, Kwak LW YONSEI MED J 2007 48 1 1-10
42. 912099 Mouse X human heterohybridomas as fusion partners with human B cell tumors. Carroll WL, Thielemans K, Dilley J, Levy R J IMMUNOL METHODS 1986 89 1 61-72
43. 912109 Development of vaccine strategies for the treatment of B-cell malignancies. Kobrin CB, Kwak LW CANCER INVEST 1997 15 6 577-587
44. 912132 Developing idiotype vaccines for lymphoma: From preclinical studies to phase III clinical trials. Park HJ, Neelapu SS BR J HAEMATOL 2008:DOI:10.1111/j.1365-2141.2008.07143.x
45. 912137 Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma. Reinis M CURR OPIN MOL THER 2007 9 3 291-298
46. 912141 A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Popescu MC, Robb RJ, Batenjany MM, Boni LT, Neville ME, Pennington RW, Neelapu SS, Kwak LW BLOOD 2007 109 12 5407-5410
47. 917051 Cancer statistics, 2008. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ CA CANCER J CLIN 2008 58 2 71-96
48. 917058 The natural history of initially untreated low-grade non-Hodgkin's lymphomas. Horning SJ, Rosenberg SA N ENGL J MED 1984 311 24 1471-1475
49. 917059 Spontaneous regression in non-Hodgkin's lymphoma: Clinical and pathogenetic considerations. Drobyski WR, Qazi R AM J HEMATOL 1989 31 2 138-141
50. 917107 Patient benefits of maintenance immunotherapy. Ghielmini M LEUK RES 2006 30 Suppl 1 S22-S26
51. 917242 Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Martin P, Furman RR, Coleman M, Leonard JP CLIN CANCER RES 2007 13 18 Pt 2 5636s-5642s
52. 917434 Non-Hodgkin lymphoma. Evans LS, Hancock BW LANCET 2003 362 9378 139-146
53. 917445 Form 10-K 2005 - Accentia BioPharmaceuticals. Accentia BioPharmaceuticals Inc FORM 10-Q 2005 December 29
54. 926103 Biovest reports results for patients treated with anticancer vaccine: BiovaxID demonstrates clinically and statistically significant improvement of disease-free survival in non-Hodgkin's lymphoma in pivotal phase 3 clinical trial. Biovest International Inc PRESS RELEASE 2008 July 17
55. 937577 Non-Hodgkin lymphoma with t(14;18): Clonal evolution patterns and cytogenetic-pathologic-clinical correlations. Aamot HV, Torlakovic EE, Eide MB, Holte H, Heim S J CANCER RES CLIN ONCOL 2007 133 7 455-470
56. 939561 BiovaxID idiotype vaccination: Active immunotherapy for follicular lymphoma. Flowers CR EXPERT REV VACCINES 2007 6 3 307-317
57. 940231 NCT00091676: Study of the BiovaxID tumor derived idiotype vaccine in patients with follicular lymphoma (BiovaxID). CLINICALTRIALS.GOV 2008